Limitations of Bu/Flu-based preparative regimen in CTLA-4 haploinsufficiency to achieving disease phenotype correction

被引：2

作者：

Parker, Loretta ^{[1
]}

Kapadia, Malika ^{[2
]}

Chellapandian, Deepak ^{[3
]}

Whangbo, Jennifer ^{[2
]}

Grace, Rachael ^{[4
]}

Prince, Chengyu ^{[5
]}

Parikh, Suhag ^{[6
]}

Bray, Robert ^{[7
]}

Gebel, Howard ^{[7
]}

Chandrakasan, Shanmuganathan ^{[8
]}

机构：

[1] Emory, Childrens Healthcare Atlanta, Atlanta, GA USA

[2] Boston Childrens, Pediat Hematopoiet Stem Cell Transplantat, Dana Farber, Boston, MA USA

[3] Johns Hopkins All Childrens Hosp, Blood & Marrow Transplant, St Petersburg, FL USA

[4] Boston Childrens, Dana Farber, Hematol Clin Res, Boston, MA USA

[5] Emory Univ, Atlanta, GA USA

[6] Emory, Childrens Healthcare Atlanta, Cellular Therapies Nonmalignant Dis, Atlanta, GA USA

[7] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA USA

[8] Emory Univ SOM, Childrens Healthcare Atlanta, Atlanta, GA USA

来源：

关键词：

CTLA-4; Busulfan; Fludarabine; HSCT; Mixed chimerism;

D O I：

10.1016/j.clim.2023.109396

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：16 / 17

页数：2